Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk Children: A UK Analysis

Abstract

Objective: To assess the cost effectiveness of palivizumab (a preventative treatment against severe respiratory syncytial virus [RSV] infection) in children at high risk of hospitalisation, i.e. preterm infantsBronchopulmonary-dysplasia, Congenital-heart-disorders, Cost-utility, Infants, Neonates, Palivizumab, Respiratory-syncytial-virus-infections